Skip to main content
Qualigen Therapeutics, Inc. logo

Qualigen Therapeutics, Inc. — Investor Relations & Filings

Ticker · QLGN ISIN · US74754R1032 US Professional, scientific and technical activities
Open in API
Filings indexed 618 across all filing types
Latest filing 2015-09-30 Director's Dealing
Country US United States of America
Listing US QLGN

About Qualigen Therapeutics, Inc.

https://qlgntx.com/

Qualigen Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for cancer. The company's efforts are directed toward creating therapeutics for both adult and pediatric patients, with a particular emphasis on rare cancers and areas of high unmet medical need. Its development approach combines internal capabilities with collaborations from major cancer research institutions. The company's investigational oncology pipeline includes programs such as QN-302, a Pan-RAS inhibitor platform, and QN-247.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2015-09-30 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is used for current reports to announce major events that shareholders should know about. The content specifically details the appointment of a new Vice President, Finance, including employment terms and background information. This fits the category of announcements related to changes in the company's board of directors or senior management. The document is not a full financial report, earnings release, or other types of filings. Therefore, it is best classified as Board/Management Information (MANG). The document length is 4363 characters, which is consistent with a detailed announcement rather than a brief notice or a full report.
2015-09-22 English
PRIMARY DOCUMENT
Director's Dealing
2015-09-01 English
FORM 10-Q
Interim / Quarterly Report Q2 2015
2015-08-12 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes an amendment to a material definitive agreement related to a clinical supply and cooperation agreement, including financial terms and stock issuance. It does not contain comprehensive financial statements or detailed financial performance data typical of annual or quarterly reports. It is not an earnings release, proxy statement, or management discussion. The document is an announcement of a material contract amendment and related corporate actions, which fits the category of Capital/Financing Update (CAP) because it involves financing terms, stock issuance, and contractual amendments affecting the company's capital and agreements. Therefore, the appropriate classification is CAP with high confidence.
2015-07-27 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement, specifically a lease agreement for office space. It does not contain financial statements or detailed financial analysis, nor is it an annual or quarterly report. The document is relatively short (3920 characters) and serves as an announcement of a significant corporate event rather than a detailed report. Therefore, it fits the category of a Regulatory Filing (RNS), which is the fallback for miscellaneous filings that do not fit other specific categories.
2015-07-14 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.